The Tear Film & Ocular Surface Society (TFOS) has announced the launch of its next global workshop, ‘A Lifestyle Epidemic: Ocular Surface Disease’. "The world around us has changed unbelievably and
Invisible computing pioneer Mojo Vision, developer of the world’s first augmented reality (AR) contact lens has partnered with contact lens manufacturer Menicon. The Mojo Lens is
US actor Johnny Depp has suffered with vision issues from early on in his life and is nearly blind in his left eye. The Hollywood movie star told Rolling Stone magazine he had “been blind as a bat” in his left eye since birth and is myopic in his right eye. Depp admitted he can barely see anything a
St George’s Eye Care celebrated its fifth anniversary in November, providing some welcome celebratory person-to-person time after the Covid-19 pandemic lockdowns.
Eschenbach has launched a first-of-its-kind low vision assessment kit, Haus Call, allowing optometrists to conduct a low vision exam and a follow-up device assessment remotely.
A long-term, large US study has found that vitamin D and omega-3 supplements have little effect on the development and progression of age-related macular degeneration (AMD).
The demand for anti-VEGF injections to stem vision loss from age-related macular degeneration (AMD) and diabetic retinopathy is continuing to rise by about 15% a year, adding to the strain on district health boards’ (DHBs’) eye care budgets, already burdened by backlogs for eye care such as cataract
The Centre for Eye Research Australia (CERA) has set up a new Health Services Research Unit investigating solutions to overcome the backlog of undiagnosed and untreated eye conditions resulting from the Covid-19 pandemic.
Glaucoma New Zealand’s (GNZ’s) annual symposium is back and will be held on 7 March 2021 at Alexandra Park in Auckland.
Australian researchers have confirmed that toxic metals accumulated in the human retina and optic nerve head can contribute to the development of age-related macular degeneration (AMD). Metals in
Allergan has released early Phase III clinical trial results demonstrating the safety and efficacy of its investigational eye drop for presbyopia treatment. “The positive results from the
